Loading
2 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Mismatch repair immunohistochemistry or microsatellite instability testing on every colorectal cancer; MLH1 promoter methylation testing where MLH1 is lost, because most of those cancers are sporadic; germline testing when methylation is absent, then cascade testing of relatives.
Tests that show whether a tumour has lost its DNA spell-checker; if so, immunotherapy works unusually well and an inherited syndrome may be present.
Histopathology means looking at cancer cells under a microscope, and immunohistochemistry stains them for specific proteins. Together they are still the foundation of every diagnosis.
A test of the DNA you were born with, to find inherited risk genes such as BRCA or Lynch syndrome.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Consider daily aspirin for more than two years (NICE NG151 1.1.1, from CAPP2); colonoscopic surveillance at intervals set by gene and age; discussion of the extent of colectomy when a cancer is found; gynaecological risk-reducing surgery after childbearing for women.
Daily low-dose aspirin lowers bowel cancer risk in people with Lynch syndrome and appears to cut recurrence in bowel cancers with a particular mutation. In healthy older people it caused more harm than good.
Drugs or surgery for people at high inherited risk, before any cancer appears.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.